Open AccessPancreatic cancer organoids recapitulate disease and allow personalized drug screening
Author(s) -
Else Driehuis,
Arne van Hoeck,
Kat Moore,
Sigrid Kolders,
Hayley E. Francies,
M. Can Gulersonmez,
Edwin C.A. Stigter,
Boudewijn Burgering,
Veerle Geurts,
Ana Gudelj Gračanin,
Gergana Bounova,
Folkert H.M. Morsink,
Robert G.J. Vries,
Sylvia F. Boj,
Johan H. van Es,
G. Johan A. Offerhaus,
Onno Kranenburg,
Mathew J. Garnett,
Lodewyk F.A. Wessels,
Edwin Cuppen,
Lodewijk A.A. Brosens,
Hans Clevers
Publication year - 2019
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1911273116
Subject(s) - pancreatic cancer , organoid , medicine , personalized medicine , pancreas , cancer , drug , cancer research , pathology , oncology , bioinformatics , biology , pharmacology , neuroscience
Significance We describe a biobank of patient-derived pancreatic cancer organoids, characterized by whole-genome DNA sequencing, RNA sequencing, and histology. The organoid biobank will be made publicly available and thus can serve as a resource for others. Pancreatic cancer organoids have been described previously; however, here we expose organoids to extensive drug screens to reveal unique drug sensitivity profiles for individual organoid lines. These findings underscore the importance of personalized approaches when using targeted agents to treat cancer in the clinic.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom